Why the study?
Does the use of CHA2DS2-VASc risk stratification and newer oral anticoagulants improve stroke prevention and simplify therapy in patients with atrial fibrillation compared to CHADS2 and vitamin K antagonists?
Does the use of CHA2DS2-VASc risk stratification and newer oral anticoagulants improve stroke prevention and simplify therapy in patients with atrial fibrillation compared to CHADS2 and vitamin K antagonists?
The transition to CHA2DS2-VASc for risk stratification and the use of newer oral anticoagulants are expected to improve patient outcomes and reduce the burden of AF-related stroke.
No takes yet. Share an insight, caveat, or question.
May support CHA2DS2-VASc and NOAC preference in AF; leaves open need for prospective validation.
Freek W.A. Verheugt (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: